QCG
ACAD icon

Quadrant Capital Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Quadrant Capital Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-308
Closed -$6.86K – 1252
2026
Q1 		$6.86K Buy
308
+280
+1,000% +$6.69K ﹤0.01% 2294
2025
Q4 		$748 Sell
28
-28
-50% -$669 ﹤0.01% 2620
2025
Q3 		$1.2K Buy
+56
New +$1.32K ﹤0.01% 2546
2025
Q2 		– Sell
-9,258
Closed -$154K – 1344
2025
Q1 		$154K Buy
+9,258
New +$168K 0.01% 1410
2024
Q4 		– Sell
-205
Closed -$3.15K – 2734
2024
Q3 		$3.15K Buy
+205
New +$3.42K ﹤0.01% 2417
2022
Q4 		– Sell
-435
Closed -$7K – 2733
2022
Q3 		$7K Buy
435
+369
+559% +$5.98K ﹤0.01% 1999
2022
Q2 		$1K Sell
66
-44
-40% -$821 ﹤0.01% 2309
2022
Q1 		$2K Sell
110
-79
-42% -$1.91K ﹤0.01% 2118
2021
Q4 		$4K Buy
189
+47
+33% +$945 ﹤0.01% 1926
2021
Q3 		$2K Sell
142
-418
-75% -$8.06K ﹤0.01% 2098
2021
Q2 		$14K Buy
560
+427
+321% +$9.64K ﹤0.01% 1374
2021
Q1 		$3K Buy
133
+27
+25% +$1.19K ﹤0.01% 1923
2020
Q4 		$6K Buy
106
+65
+159% +$3.23K ﹤0.01% 1610
2020
Q3 		$2K Buy
+41
New +$1.77K ﹤0.01% 1781
2020
Q2 		– Sell
-968
Closed -$41K – 2199
2020
Q1 		$41K Sell
968
-181
-16% -$7.46K 0.01% 958
2019
Q4 		$48K Buy
1,149
+181
+19% +$7.87K 0.01% 1354
2019
Q3 		$34K Hold
968
– – 0.01% 1376
2019
Q2 		$25K Buy
+968
New +$24.7K ﹤0.01% 1544
2017
Q1 		– Sell
-2,345
Closed -$67K – 2057
2016
Q4 		$67K Sell
2,345
-236
-9% -$6.24K 0.03% 351
2016
Q3 		$81K Buy
2,581
+2,351
+1,022% +$79.7K 0.05% 294
2016
Q2 		$7K Buy
+230
New +$7.7K ﹤0.01% 1111
2016
Q1 		– Sell
-179
Closed -$6K – 1791
2015
Q4 		$6K Buy
+179
New +$6.31K ﹤0.01% 959

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Quadrant Capital Group's ACAD Position: Q2 2026 in Review

Quadrant Capital Group sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 308 shares — an estimated $6.86K sold.

Quadrant Capital Group first reported a position in ACAD in Q4 2015 and held it in 22 quarters. The position peaked at $154K in Q1 2025. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Quadrant Capital Group reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 308 Acadia Pharmaceuticals shares in Q2 2026, an estimated $6.86K.
  • Quadrant Capital Group first reported a position in Acadia Pharmaceuticals in Q4 2015 and held it in 22 quarters.
  • Quadrant Capital Group's Acadia Pharmaceuticals position peaked at $154K in Q1 2025.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.